What are the treatment options for Small Intestine Bacterial Overgrowth (SIBO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Small intestinal bacterial overgrowth (SIBO) is typically treated with antibiotics, with rifaximin being the most commonly prescribed option, as evidenced by the most recent study 1. The treatment of SIBO involves reducing the excessive bacteria in the small intestine, and antibiotics are the primary treatment option.

Treatment Options

  • The most commonly prescribed antibiotic is rifaximin (Xifaxan) at a dose of 550 mg three times daily for 14 days, as supported by 1.
  • For methane-predominant SIBO, a combination of rifaximin with neomycin (500 mg twice daily) or metronidazole (250-500 mg three times daily) for 10-14 days may be more effective, as suggested by 1.
  • Alternative antibiotics include ciprofloxacin, doxycycline, or amoxicillin-clavulanate if the first-line options aren't suitable, as mentioned in 1 and 1.

Additional Therapies

  • Following antibiotic treatment, a prokinetic agent like low-dose erythromycin (50-100 mg at bedtime) or prucalopride may help prevent recurrence by improving intestinal motility, as noted in 1.
  • Dietary modifications are also important during and after treatment, with many patients benefiting from a low FODMAP diet to reduce fermentable carbohydrates that feed bacteria, although this is not explicitly mentioned in the provided studies.

Considerations

  • Recurrence is common, so addressing underlying causes such as adhesions, motility disorders, or anatomical issues is crucial for long-term management, as highlighted in 1.
  • The risk of resistant organisms, including Clostridioides difficile, should also be considered when using antibiotics, as warned in 1.

From the FDA Drug Label

The efficacy of XIFAXAN for the treatment of IBS-D was established in 3 randomized, multi‑center, double-blind, placebo-controlled trials in adult patients.

The treatment options for Small Intestine Bacterial Overgrowth (SIBO) are not directly addressed in the provided drug label. However, Rifaximin is mentioned as a treatment for Irritable Bowel Syndrome with Diarrhea (IBS-D), which may be related to SIBO.

  • Rifaximin 550 mg three times a day for 14 days is a recommended treatment for IBS-D. However, the label does not provide direct information on the treatment of SIBO. 2

From the Research

Treatment Options for Small Intestine Bacterial Overgrowth (SIBO)

  • Antibiotic therapy is a common treatment approach for SIBO, with rifaximin being a preferred option due to its efficacy in eradicating SIBO and improving symptoms 3, 4, 5
  • Rifaximin has been shown to be effective in treating hydrogen-positive SIBO, with response rates of 47.4% for hydrogen positivity alone and 80% for both hydrogen and methane positivity 3
  • Broad-spectrum antibiotics such as amoxicillin, ciprofloxacin, and metronidazole may also be used to treat SIBO, although evidence for their use is fair 6
  • A multifaceted approach including a low-FODMAP diet, antimicrobial botanical therapy, and homeopathic medicine may also be effective in treating SIBO and its associated symptoms 7
  • Elemental diet and promotility drugs may also be used to induce and maintain remission in SIBO patients 6

Comparison of Antibiotic Therapies

  • Rifaximin has been shown to be more effective than metronidazole in normalizing glucose breath test results, with a higher SIBO decontamination rate and better tolerability 5
  • Rifaximin has also been compared to other antibiotics, with studies suggesting that it is a good choice for the management of patients affected by SIBO 4, 5

Dietary Modifications

  • A low-FODMAP diet may be beneficial in enhancing antibiotic therapy and reducing symptoms of SIBO 7
  • Dietary modifications may be used in conjunction with antibiotic therapy to induce and maintain remission in SIBO patients 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 2019

Research

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

European review for medical and pharmacological sciences, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.